User:Mr. Ibrahem/Panitumumab

Panitumumab, sold under the brand name Vectibix, is a medication used for colorectal cancer that has spread to other parts of the body. It may be used alone or together with other medications for tumors that have normal RAS genes. It is used when other treatments have failed. It is given gradually into a vein.

Common side effects include diarrhea, nausea, abdominal pain, tiredness, fever, rash, itchiness, and dry skin. Other concerns include pulmonary fibrosis, infertility, and sepsis. Use during pregnancy may harm the baby. It is a monoclonal antibody that attaches to and blocks epidermal growth factor receptor (EGFR).

Panitumumab was approved for medical use in the United States in 2006. It was conditionally approved in Europe in 2007 and fully approved in 2015. In the United Kingdom it costs the NHS about £1,500 per 400 mg as of 2021. This amount in the United States costs about 5,700 USD.